These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 7737945)

  • 1. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte-reduced blood components in transfusion medicine. Current indications and prospects for the future.
    Klapper EB; Goldfinger D
    Clin Lab Med; 1992 Dec; 12(4):711-21. PubMed ID: 1286560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocyte depletion of cellular blood components.
    Lane TA
    Curr Opin Hematol; 1994 Nov; 1(6):443-51. PubMed ID: 9371321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in transfusion therapy.
    Beck SJ
    Clin Lab Sci; 1994; 7(4):225-31. PubMed ID: 10147432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 6. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs.
    Lane TA
    Arch Pathol Lab Med; 1994 Apr; 118(4):392-404. PubMed ID: 8166589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte reduction in blood component therapy.
    Lane TA; Anderson KC; Goodnough LT; Kurtz S; Moroff G; Pisciotto PT; Sayers M; Silberstein LE
    Ann Intern Med; 1992 Jul; 117(2):151-62. PubMed ID: 1605430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte-reduced blood components: patient benefits and practical applications.
    Higgins VL
    Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection.
    Rawal BD; Davis RE; Busch MP; Vyas GN
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Why remove leukocytes from labile blood products in 1995?].
    Andreu G; Belhocine R; Klaren J; Fretz C; Lejus C
    Transfus Clin Biol; 1996; 3(1):57-74. PubMed ID: 8640315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy.
    Bordin JO; Blajchman MA
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):205-18. PubMed ID: 7737942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion strategies in patients undergoing stem-cell transplantation.
    Radia R; Pamphilon D
    Expert Rev Hematol; 2011 Apr; 4(2):213-20. PubMed ID: 21495930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk of immunization to blood cells and diagnostic and therapeutic implications].
    Kiefel V
    Beitr Infusionsther; 1993; 31():44-51. PubMed ID: 7693263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes.
    Lee JH; Klein HG
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):585-600. PubMed ID: 11102278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.
    Erhabor O; Adias TC
    Transfus Clin Biol; 2011 Dec; 18(5-6):516-26. PubMed ID: 22037104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical issues in neonatal transfusion practice.
    Strauss RG
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S57-63. PubMed ID: 9124231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.